Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00922324 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of STP206 in Healthy Adult Subjects
A Phase 1 study of Healthy, sponsored by Leadiant Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00922324 is a Phase 1 study of Healthy that has completed, run by Leadiant Biosciences. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00922324, a Phase 1 study of Healthy, has completed, sponsored by Leadiant Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the safety, tolerability and fecal shedding of STP206 when given as a single dose and when given as daily doses for one week.
Conditions Studied
Interventions
- DRUG STP206 or vehicle control
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00922324
The ClinicalTrials.gov registry entry for NCT00922324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Leadiant Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which STP206 or vehicle control is the first listed.
NCT00922324 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00922324 about?
NCT00922324 is a clinical study titled "Safety and Tolerability of STP206 in Healthy Adult Subjects". The study will assess the safety, tolerability and fecal shedding of STP206 when given as a single dose and when given as daily doses for one week.
What is the current status of trial NCT00922324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-03. Estimated completion is 2010-11.
What conditions does trial NCT00922324 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00922324?
The interventions under investigation include: STP206 or vehicle control (DRUG).
Who is sponsoring clinical trial NCT00922324?
This trial is sponsored by Leadiant Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00922324 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.